gpt-dict.com

AI evidence summary · MVP

Fisetin for Aging

AI preliminary evidence assessment

U

U 級｜AI 整體初步評級

This preliminary assessment is currently available in Traditional Chinese.

Exact question一般成人口服單方非瑟酮，相較安慰劑、不使用或常規照護，是否能延緩具臨床意義的老化相關退化？

目前有人體代理指標與有限安全性資料，但沒有直接符合本題、報告具臨床意義老化結果的效益研究；證據不足以支持本題的臨床效果。

Why this assessment was given

  • 10名健康成人中，4人的生物年齡下降、5人上升，整體呈現方向不一致的觀察結果。
Limitations affecting this assessment
  • 沒有任何研究符合預先界定的病人重要主要結局與適用族群條件；移除療效追蹤期門檻後仍為零篇，缺乏證據不得解讀為無效。
  • 10人健康成人先導研究僅評估生物年齡：4/10下降、5/10上升、1/10不變，且摘要未報告對照組；此代理指標不能證明臨床抗老效益。
  • 41名高齡成人的隨機安慰劑對照會議摘要報告血流介導擴張改善，但這是血管生理代理指標、尚未完整同儕審查，且可能只是未完成登錄試驗的部分樣本；研究材料由Life Extension提供。
  • NCT04313634主要涉及骨轉換、骨密度及衰老相關代理指標；登錄未提供非瑟酮對未治療組的主要推論分析，且非瑟酮組僅14人、完成12人。
  • 兩項健康老化研究僅為尚無結果的研究協定，不能納入療效或安全性判斷。
  • 海灣戰爭疾病研究的症狀結果屬疾病特異族群；達沙替尼、槲皮素與非瑟酮研究為混合介入；藥物動力學研究只評估單次吸收，均不能直接回答本問題。
  • 多份人體報告僅有摘要或登錄資料，完整方法未取得；可能影響偏倚、停藥、失訪與結果選擇性報告的判斷。
  • 安全性事件未作因果歸屬，且研究規模不足以排除罕見或長期傷害。

Human evidence currently available

Findings are currently provided in Traditional Chinese; source excerpts retain their original language.

Exploratory human finding 1

6個月；每月服用1週

10名健康成人中，4人的生物年齡下降、5人上升，整體呈現方向不一致的觀察結果。

Applicability assessment: 研究直接在50歲以上健康成人中評估非瑟酮與生物老化，但臨床療效終點仍未界定。

Population
50歲以上健康成人
Intervention
口服非瑟酮
Comparator
摘要未報告對照組
Outcome
以TruAge檢測評估的生物年齡變化
Follow-up
6個月；每月服用1週
Formulation
Not established
Dose
500 mg daily for one week per month
Source excerpt: four out of ten healthy adults experienced a reduction in biological aging, five out of ten saw an increase
View source

Research protocol 2

3週

試驗計畫評估三週非瑟酮療程是否減少脂肪活檢中的衰老細胞；摘要尚無結果。

Applicability assessment: 計畫直接研究健康高齡者的老化生物機制，但尚未報告結果。

Population
70歲以上健康成人，計畫男女各30名
Intervention
非瑟酮
Comparator
另設二甲雙胍緩釋劑與亞精胺試驗組；摘要未述安慰劑組
Outcome
脂肪活檢中以SA-β-GAL測量的衰老細胞數量
Follow-up
3週
Formulation
Not established
Dose
100 mg
Source excerpt: The primary research question will answer whether a three-week course of Metformin, Spermidine, or Fisetin reduce the number of senescent cells
View source

Research protocol 3

7週

計畫將50歲以上成人隨機分配接受每日100 mg口服非瑟酮或安慰劑，共7週；摘要尚無結果。

Applicability assessment: 計畫研究中高齡成人的慢性發炎、老化與細胞衰老指標，但尚未提供結果。

Population
一般健康、年齡至少50歲的中年與高齡成人
Intervention
每日口服非瑟酮補充劑
Comparator
安慰劑
Outcome
基線至第7週血漿可溶性尿激酶型纖溶酶原活化劑受體（suPAR）變化的組間差異
Follow-up
7週
Formulation
Not established
Dose
100 mg once daily
Source excerpt: Participants aged ≥ 50 will be randomised to receive 100 mg of oral fisetin or placebo once daily for 7 weeks.
View source

Scope-limited human finding 4

6個月

達沙替尼、槲皮素與非瑟酮合併治療後，表觀遺傳年齡加速呈未達顯著的增加；此結果不能歸因於非瑟酮單一成分。

Applicability assessment: 研究涉及表觀遺傳老化，但採用三種成分的合併介入，無法回答非瑟酮單獨對一般老化健康的效果。

Population
19名參與者，其中10名曾參加先前的達沙替尼與槲皮素研究
Intervention
達沙替尼、槲皮素與非瑟酮合併治療
Comparator
先前接受達沙替尼與槲皮素合併治療的研究組
Outcome
DNA甲基化及表觀遺傳年齡加速
Follow-up
6個月
Formulation
Not established
Dose
Not established
Source excerpt: the addition of Fisetin to the treatment resulted in non-significant increases in epigenetic age acceleration
View source

Pharmacokinetic context 5

單次給藥

此研究僅評估藥物動力學與生體可用率，不能回答一般老化健康問題。

Applicability assessment: 僅評估吸收與暴露。

Population
健康志願者
Intervention
FF-20非瑟酮配方
Comparator
未配方非瑟酮
Outcome
非瑟酮與代謝物的血漿暴露
Follow-up
單次給藥
Formulation
Not established
Dose
1000 mg FF-20（提供192 mg非瑟酮）或1000 mg未配方非瑟酮
Source excerpt: This is the first human pharmacokinetic study of fisetin following a single-dose, comparative, double-blinded, cross-over protocol
View source

Scope-limited human finding 6

各劑量階段1個月

在海灣戰爭疾病受試者中，非瑟酮低劑量與高劑量均未比安慰劑降低症狀嚴重度。

Applicability assessment: 疾病特異性族群與結局不能直接回答一般人體老化健康問題。

Population
完成研究的21名海灣戰爭疾病男性退伍軍人
Intervention
低劑量及高劑量非瑟酮
Comparator
安慰劑
Outcome
海灣戰爭疾病症狀嚴重度
Follow-up
各劑量階段1個月
Formulation
Not established
Dose
Not established
Source excerpt: fisetin did not reduce symptom severity at either the lower (p = 0.504) or higher (p = 0.616) dosages.
View source

Exploratory human finding 7

兩個3日療程

41名高齡成人的會議摘要報告，短期間歇使用非瑟酮後，肱動脈血流介導擴張較安慰劑改善。

Applicability assessment: 只報告短期血管生理代理指標，不能回答一般抗老化臨床效益。

Population
41名高齡成人
Intervention
短期間歇口服非瑟酮
Comparator
安慰劑
Outcome
肱動脈血流介導擴張（血管生理代理指標）
Follow-up
兩個3日療程
Formulation
Not established
Dose
2 mg/kg/day
Source excerpt: FMDBA was improved by 41% with fisetin (pre: 3.9±0.4%, post: 5.5±0.5%, P< 0.0001), but unchanged with placebo
View source

Exploratory human finding 8

約20週

NCT04313634 登錄結果顯示非瑟酮組起始14人、完成12人；主要結果為骨轉換指標。

Applicability assessment: 效益結果僅為代理指標；安全事件可直接納入安全性軸，但樣本小且沒有因果判定。

Population
74名健康停經後女性，其中非瑟酮組14名、未治療組30名
Intervention
間歇口服單方非瑟酮
Comparator
未治療組
Outcome
骨轉換代理指標與安全性事件
Follow-up
約20週
Formulation
Not established
Dose
約20 mg/kg/day，每28日連續3日，共5次
Source excerpt: "numSubjects":"14"
View source

Safety finding 9

約20週

NCT04313634 登錄結果顯示，EG001（非瑟酮組）有1/14人發生胃出血嚴重不良事件，EG002（未治療組）為0/30。

Applicability assessment: 效益結果僅為代理指標；安全事件可直接納入安全性軸，但樣本小且沒有因果判定。

Population
74名健康停經後女性，其中非瑟酮組14名、未治療組30名
Intervention
間歇口服單方非瑟酮
Comparator
未治療組
Outcome
骨轉換代理指標與安全性事件
Follow-up
約20週
Formulation
Not established
Dose
約20 mg/kg/day，每28日連續3日，共5次
Source excerpt: "stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":30}],"term":"Gastric hemorrhage"
View source

Safety finding 10

約20週

NCT04313634 受試者流程顯示，FG001（非瑟酮組）有2/14人因不良事件未完成研究，FG002（未治療組）為0/30。

Applicability assessment: 效益結果僅為代理指標；安全事件可直接納入安全性軸，但樣本小且沒有因果判定。

Population
74名健康停經後女性，其中非瑟酮組14名、未治療組30名
Intervention
間歇口服單方非瑟酮
Comparator
未治療組
Outcome
骨轉換代理指標與安全性事件
Follow-up
約20週
Formulation
Not established
Dose
約20 mg/kg/day，每28日連續3日，共5次
Source excerpt: "reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Adverse Event"
View source

Sources consulted

  1. Intermittent fisetin treatment improves vascular endothelial function and suppresses cellular senescence in older adults: role of reduced mitochondria-related oxidative stress Context source; not counted as an included human-result report Abstract only · 2026-09-15T00:00:00Z
  2. Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans Context source; not counted as an included human-result report Metadata only · 2026-09-15T00:00:00Z
  3. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea). Context source; not counted as an included human-result report Abstract only · 2026-09-15T00:00:00Z
  4. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. Context source; not counted as an included human-result report Abstract only · 2026-09-15T00:00:00Z
  5. Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions. Context source; not counted as an included human-result report Abstract only · 2026-09-15T00:00:00Z
  6. The Effects of Fisetin on Reducing Biological Aging: A Pilot Study. Context source; not counted as an included human-result report Abstract only · 2026-09-15T00:00:00Z
  7. REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect: Rationale and protocol for a trial of biological effect. Context source; not counted as an included human-result report Abstract only · 2026-09-15T00:00:00Z
  8. Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial. Context source; not counted as an included human-result report Abstract only · 2026-09-15T00:00:00Z

Reading and assessment notes

Grade U means the verified evidence is insufficient to support a clinical effect for this defined question; it does not establish no effect. Read the method and common limitations.

Absence of reported harms does not establish safety. This summary does not provide individual treatment or dosing advice.

Data and assessment record

Search coverage for this case

主要 PubMed 候選池去重後238筆；另以精確臨床結果查詢取得7筆 PubMed 紀錄，並以非瑟酮介入查詢取得36筆 ClinicalTrials.gov 登錄。來源之間可能重複，因此7與36不另加到238筆唯一候選數。

Searched：2026-09-15T03:20:17.285612Z · Databases：PubMed、ClinicalTrials.gov

238 records identified; 238 screened; 0 reports from 0 unique study populations included.

Some included reports were assessed without full text.

  • 僅完成有界的 PubMed 與 ClinicalTrials.gov 查詢，未檢索其他書目資料庫。
  • 部分原始全文與附錄未取得，也未完成完整引文追查。

Processing record

Evidence summary available

Sources through：2026-09-15 · Generated：2026-09-15T04:08:12.627689Z

Retrieved 238 records · Screened 238 · Included 0 reports · Omitted 238

Run：rating-candidate-v6

codex_cli / gpt-5.6-sol / problem-search-source-bound-l2+l11-v1

{
  "included": 0,
  "limits_hit": [
    "fulltext_unavailable",
    "limited_citation_tracing"
  ],
  "omitted": 238,
  "retrieved": 238,
  "screened": 238
}

sha256:b50327e6ee14ca006e7662c7cf4cf786d0f0a0a34e65c0b82ed9ed665a40046d